Table 3 Multivariable analysis for cumulative incidence of relapse, relapse free survival and overall 608 survival including to the number of persisting mutations.

From: Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

 

CIR

RFS

OS

HR

CI

P-value

HR

CI

P-value

HR

CI

P-value

NGS MRD neg

1

  

1

  

1

  

NGS MRD 1 mut

1.92

0.94–3.92

0.072

1.58

0.85–2.95

0.15

1.60

0.77–3.35

0.21

NGS MRD 2 or more mut

3.71

1.82–7.56

< 0.0001

3.36

1.83–6.17

< 0.0001

3.81

1.87–7.74

0.00023

ELN2017 FAV

1

  

1

  

1

  

ELN2017 INT

1.78

0.89–3.57

0.10

1.60

0.87–2.96

0.13

1.76

0.83–3.75

0.14

ELN2017 ADV

1.36

0.63–2.94

0.43

1.53

0.80–2.93

0.20

2.26

1.05–4.87

0.037

Age

1.01

0.98–1.04

0.57

1.00

0.98–1.03

0.88

1.00

0.87–1.03

0.89

  1. HR Hazard ratio, CI 95% confidence interval, FAV favorable, INT intermediate, ADV adverse, CIR cumulative incidence of relapse, RFS relapse-free survival, OS overall survival.
Back to article page